Subscribe to Search results

The South West Regional Transfusion Centre stopped collecting donations from prisons.

Published on:

Dr John Wallace, the senior Scottish National Blood Transfusion Service director, stated in "Blood Transfusion for Clinicians" that it was socially and psychologically undesirable to exclude prisoners from blood donation.

Published on:

Scottish National Blood Transfusion Service directors considered the collection of blood in prisons and borstals. The meeting did not agree on future policy.

Published on:

Dr Brookes reported to Scottish National Blood Transfusion Service directors her consultation with the English/Welsh transfusion directors concerning collections in prisons and borstals.

Published on:

Belfast held its last prison donor session at HMP Belfast (Crumlin Road Jail), Magilligan HM Prison, Limavady, Co Londonderry.

Published on:

An article in The British Medical Journal discussed how a recent outbreak of hepatitis after prophylactic serum aroused controversy and drew attention to the dangers of hepatitis associated with immunisation.

Published on:

A study by Feinstone et al identified infectious hepatitis as Hepatitis A in 1973.

Published on:

Findlay and MacCallum considered cases of hepatitis following yellow fever vaccination, the possible explanations for this and considered whether a virus capable of producing jaundice in humans was capable of being the source.

Published on:

The Scottish National Report for 1973 stated that routine screening of all donated blood for the presence of hepatitis-associated antigen had been in place for a year or longer in some centres.

Published on:

A World Health Organization Scientific Group report on viral hepatitis stated that the present techniques for detecting Hepatitis B antigen were thought capable of preventing up to 30% of post-transfusion hepatitis, which were deemed more sensitive than earlier techniques.

Published on:

The NHS advisory report on testing for Hepatitis B described the methods available for detecting HBsAg and anti-HBs and recommended that CIE should no longer be used and that regional transfusion centres should use either reverse passive haemagglutination or radioimmunoassay.

Published on:

Dr Rosemary Biggs predicted that within the next two years very large amounts of commercial products would become available in the US, and the UK would be obliged to purchase them at a high cost if it did not make urgent plans to meet its domestic demand.

Published on:

Dr Garrott Allen found that prison blood accounted for 90% of post-transfusion icteric hepatitis.

Published on:

It was raised at a UKHCDO meeting that Immuno would start selling Kryobulin Factor 8 concentrate at two prices.

Published on:

Professor Ingram asked Professor Charles Rizza to update the UKHCDO meeting minutes regarding the Immuno products.

Published on:

Immuno considered that the British market would accept a higher risk of hepatitis for a lower-priced product.

Published on:

An article in The Lancet expressed concerns about the long-term consequences of non-A non-B Hepatitis.

Published on:

Professor Zuckerman concluded that the use of blood concentrates should be restricted to life-threatening situations until blood donors could be screened for non-A non-B Hepatitis.

Published on:

Armour Pharmaceutical published information about the current state of knowledge regarding non-A non-B Hepatitis.

Published on:

An article was published which assessed the severity of liver disease in people with haemophilia.

Published on: